Free Trial
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel Free STAB Stock Alerts

Statera Biopharma (STAB) Competitors

Statera Biopharma logo
$0.0001 0.00 (0.00%)
As of 10/13/2026 01:56 PM Eastern
Compare

STAB vs. EVLO, CMRA, ADTX, EFTR, and SMFL

Should you buy Statera Biopharma stock or one of its competitors? Statera Biopharma's main competitors and comparable companies include Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Aditxt (ADTX), eFFECTOR Therapeutics (EFTR), and Smart for Life (SMFL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Statera Biopharma compare to Evelo Biosciences?

Statera Biopharma (NASDAQ:STAB) and Evelo Biosciences (NASDAQ:EVLO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Statera Biopharma has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market. Comparatively, Evelo Biosciences has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Evelo BiosciencesN/AN/A-$114.53M-$0.66N/A

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Evelo Biosciences N/A N/A N/A

0.3% of Evelo Biosciences shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by company insiders. Comparatively, 1.0% of Evelo Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Evelo Biosciences'average media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Evelo Biosciences Neutral

Summary

Evelo Biosciences beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

How does Statera Biopharma compare to Comera Life Sciences?

Comera Life Sciences (NASDAQ:CMRA) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, profitability, analyst recommendations, risk and valuation.

Comera Life Sciences has a beta of 1.04, meaning that its share price is 4% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market.

Statera Biopharma has lower revenue, but higher earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.18N/A
Statera BiopharmaN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Statera Biopharma N/A N/A N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Statera Biopharma Neutral

Summary

Comera Life Sciences beats Statera Biopharma on 3 of the 3 factors compared between the two stocks.

How does Statera Biopharma compare to Aditxt?

Statera Biopharma (NASDAQ:STAB) and Aditxt (NASDAQ:ADTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.

Statera Biopharma has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Statera Biopharma's return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Aditxt -360,152.50%-374.60%-105.93%

Statera Biopharma has higher earnings, but lower revenue than Aditxt.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Aditxt$14.34K0.13-$41.71M-$100.79 thousandN/A

Statera Biopharma has a beta of 0.05, meaning that its share price is 95% less volatile than the broader market. Comparatively, Aditxt has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Statera Biopharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Aditxt Neutral

15.5% of Aditxt shares are held by institutional investors. 5.5% of Statera Biopharma shares are held by insiders. Comparatively, 0.0% of Aditxt shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Aditxt beats Statera Biopharma on 5 of the 9 factors compared between the two stocks.

How does Statera Biopharma compare to eFFECTOR Therapeutics?

eFFECTOR Therapeutics (NASDAQ:EFTR) and Statera Biopharma (NASDAQ:STAB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends, media sentiment and valuation.

57.7% of eFFECTOR Therapeutics shares are held by institutional investors. 4.7% of eFFECTOR Therapeutics shares are held by company insiders. Comparatively, 5.5% of Statera Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

eFFECTOR Therapeutics has a beta of 2.73, suggesting that its stock price is 173% more volatile than the broader market. Comparatively, Statera Biopharma has a beta of 0.05, suggesting that its stock price is 95% less volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
eFFECTOR TherapeuticsN/A N/A N/A
Statera Biopharma N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
eFFECTOR TherapeuticsN/AN/A-$35.81M-$8.83N/A
Statera BiopharmaN/AN/AN/AN/AN/A

In the previous week, eFFECTOR Therapeutics' average media sentiment score of 0.00 equaled Statera Biopharma'saverage media sentiment score.

Company Overall Sentiment
eFFECTOR Therapeutics Neutral
Statera Biopharma Neutral

Summary

eFFECTOR Therapeutics beats Statera Biopharma on 3 of the 4 factors compared between the two stocks.

How does Statera Biopharma compare to Smart for Life?

Statera Biopharma (NASDAQ:STAB) and Smart for Life (NASDAQ:SMFL) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Statera Biopharma has higher earnings, but lower revenue than Smart for Life.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Statera BiopharmaN/AN/AN/AN/AN/A
Smart for Life$11.11M0.00-$22.68M-$14.48N/A

Company Net Margins Return on Equity Return on Assets
Statera BiopharmaN/A N/A N/A
Smart for Life N/A N/A N/A

28.4% of Smart for Life shares are owned by institutional investors. 5.5% of Statera Biopharma shares are owned by insiders. Comparatively, 31.7% of Smart for Life shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Statera Biopharma's average media sentiment score of 0.00 equaled Smart for Life'saverage media sentiment score.

Company Overall Sentiment
Statera Biopharma Neutral
Smart for Life Neutral

Statera Biopharma has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market. Comparatively, Smart for Life has a beta of 17.74, suggesting that its share price is 1,674% more volatile than the broader market.

Summary

Smart for Life beats Statera Biopharma on 5 of the 5 factors compared between the two stocks.

Get Statera Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for STAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STAB vs. The Competition

Export
MetricStatera BiopharmaPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1K$12.13B$7.18B$13.18B
Dividend YieldN/A2.63%2.52%19.60%
P/E Ratio0.00641.56203.7919.22
Price / SalesN/A749.43557.6574.70
Price / CashN/A84.0876.6852.75
Price / BookN/A9.1510.515.92
Net IncomeN/A$2.82B$3.50B$380.90M
7 Day PerformanceN/A-3.80%-3.51%-3.85%
1 Month PerformanceN/A-7.64%-7.77%-6.37%
1 Year PerformanceN/A-6.14%0.80%-6.01%

Statera Biopharma Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
STAB
Statera Biopharma
N/A$0.00
flat		N/A+0.0%$1KN/AN/A46
EVLO
Evelo Biosciences
N/A$0.00
flat		N/AN/A$4KN/AN/A66
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
ADTX
Aditxt
0.0381 of 5 stars		$0.00
-3.3%		N/A-100.0%$2K$14.34KN/A26
EFTR
eFFECTOR Therapeutics
N/A$0.00
flat		N/AN/A$1KN/AN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:STAB) was last updated on 10/15/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel